Navigation Links
Oncolytics Biotech(R) Inc. Research Collaborators Present Glioma Reovirus Research at ASV Annual Meeting
Date:7/15/2009

velopment of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I/II and Phase II human trials using REOLYSIN, its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit www.oncolyticsbiotech.com.

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the implication of the abstracts and materials presented at this meeting with respect to REOLYSIN, the Company's expectations related to the results of trials investigating delivery of REOLYSIN, and the Company's belief as to the potential of REOLYSIN as a cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN as a cancer treatment, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize REOLYSIN, uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements, except as required by applicable laws.


'/>"/>
SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Oncolytics Biotech(R) Inc. Completes Patient Enrolment in U.K. Combination REOLYSIN(R) and Paclitaxel/Carboplatin Head and Neck Cancer Trial
2. Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at ASCO Annual Meeting
3. Oncolytics Biotech(R) Inc.s Research Collaborators to Present Data on REOLYSIN(R) Clinical Trials at ASCO Conference
4. Oncolytics(R) Biotech Inc. Completes Patient Enrolment in U.S. Phase 2 Sarcoma Study
5. Oncolytics Biotech(R) Inc. Announces 2009 First Quarter Results
6. Oncolytics Biotech(R) Inc. Announces Details of 2009 Annual Shareholder Meeting
7. Media Advisory - Oncolytics Biotech(R) Inc. to Present at BioFinance 2009
8. Oncolytics Biotech(R) Inc. Announces Positive Results of U.K. Phase II REOLYSIN(R) and Radiation Combination Clinical Trial
9. Oncolytics Biotech(R) Inc. Completes Enrolment in Combination REOLYSIN(R)/Gemcitabine Trial
10. Oncolytics Biotech(R) Inc. Collaborators Present Reovirus Research at Replicating Oncolytic Virus Meeting
11. Oncolytics Biotech(R) Inc. Collaborators Present Positive Head and Neck Results in Phase I/II Combination REOLYSIN(R) and Paclitaxel/Carboplatin Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... at The University of Manchester have generated a new star-shaped ... complex of its kind ever created. , Known ... to create one for over a quarter of a century ... Nature Chemistry . , Consisting of two molecular triangles, ... structure,s interlocked molecules are tiny each triangle is 114 ...
(Date:9/22/2014)... 22, 2014 US demand to rise 3.9% ... biocides is forecast to rise 3.9 percent per year ... is projected to increase 1.3 percent per year to ... rebound in construction expenditures will support demand for biocides ... while growth in consumer spending and manufacturing output will ...
(Date:9/22/2014)... Invisible Sentinel Inc., a life-sciences ... and beverage industries, announced today that its first-in-class ... non-exclusive agreement by Enartis, a global provider of ... Esseco Group company headquartered in Trecate, Italy, will ... other global markets for their own in-winery use ...
(Date:9/22/2014)... LONDON , September 22, 2014 ... ended on a mixed note as the Dow Jones ... NASDAQ Composite closed at 4,579.79, down 0.30%. The S&P ... the trading session, six out of ten sectors finished ... Sector Index ended the day at 751.48, up 0.10%, ...
Breaking Biology Technology:US Biocides Market 2US Biocides Market 3Invisible Sentinel's Test for Wine-Spoilage Microbe to be Distributed by Enartis in Multiple Markets Globally 2Invisible Sentinel's Test for Wine-Spoilage Microbe to be Distributed by Enartis in Multiple Markets Globally 3Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 2Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 3Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 4Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 5
... 2011 Bacterin International Holdings, Inc. (NYSE Amex: ... revolutionary bone graft material and antimicrobial coatings for medical applications, ... Healthcare Conference. The conference will be held at the Four ... Bacterin,s chairman and CEO, Guy Cook, and CFO, John ...
... NEWTOWN SQUARE, Pa., Aug. 24, 2011 Kibow Biotech, ... worldwide licensing and marketing agreement with the current licensing ... a patented, 100% natural, probiotic dietary supplement indicated for ... moderate to severe renal failure. Developed by Kibow, Azodyl™ ...
... generated stem cells from one of the most rapidly progressing ... into the condition as it will enable scientists to model ... certain nerve cells die. Scientists, funded with a 300,000 ... a patient diagnosed with one of the most progressive types ...
Cached Biology Technology:Bacterin International to Present at Stifel Nicolaus 2011 Healthcare Conference on September 8, 2011 2Kibow Biotech, Inc. Secures $2.4 Million Towards Its Human Clinical Trials by Continued Veterinary Licensing Agreement 2Stem cell study offers hope for Parkinson's patients 2
(Date:9/22/2014)... areas of sea ice melt in the summer and when ... thinner and more reduced. As the Arctic summers are getting ... reduced sea ice in the Arctic will remove less CO2 ... are representative, then sea ice plays a greater role than ... global CO2 budgets", says Dorte Haubjerg Sgaard, PhD Fellow, Nordic ...
(Date:9/21/2014)... of cowpea (black-eyed peas) is a fascinating example of ... fascinating is the story of the scientist behind the ... Legume of the 21st Century to serve as an ... book was recently published by the Crop Science Society ... Agriculture (IITA). , Singh has devoted his life,s work ...
(Date:9/21/2014)... and barnacles secrete very sticky proteins that help them ... by these natural adhesives, a team of MIT engineers ... repair ships or help heal wounds and surgical incisions. ... researchers engineered bacteria to produce a hybrid material that ... bacterial protein found in biofilms slimy layers formed ...
Breaking Biology News(10 mins):Arctic sea ice helps remove CO2 from the atmosphere 2Engineered proteins stick like glue -- even in water 2Engineered proteins stick like glue -- even in water 3
... R.I. [Brown University] The cactus, stalwart of the desert, ... plant communities found the world over. In a paper ... the National Academy of Sciences , Brown University biologists and ... between 5 and 10 million years ago and coincided with ...
... NEW ... in Brazil,s Pantanal and Cerrado regions can benefit both cattle and wildlife, ... , The technique, which has been adapted for a variety of ... periods of time before moving onto other pastures. The result is a ...
... Osama bin Laden,s leadership, al Qa,ida has been one ... responsible for more than 10,000 deaths and injuries in ... http://www.start.umd.edu/start/publications/br/BackgroundReport_AQAttacks.pdf > by the National Consortium for the Study ... of Maryland (START) . "Al-Qa,ida, the terrorist ...
Cached Biology News:Succulent plants waited for cool, dry Earth to make their mark 2Succulent plants waited for cool, dry Earth to make their mark 3Grazing as a conservation tool 2Bin Laden's attacks among the most lethal: UMD study 2